Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
McKesson
Queensland Health
Teva
Daiichi Sankyo
Harvard Business School
UBS
Federal Trade Commission
Chubb

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,940,718

« Back to Dashboard

Summary for Patent: 8,940,718
Title:Antiviral compounds
Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Bacon; Elizabeth M. (Burlingame, CA), Cottell; Jeromy J. (Redwood City, CA), Katana; Ashley Anne (San Mateo, CA), Kato; Darryl (San Francisco, CA), Krygowski; Evan S. (Washington, DC), Link; John O. (San Francisco, CA), Taylor; James (San Mateo, CA), Tran; Chinh Viet (San Mateo, CA), Martin; Teresa Alejandra Trejo (Union City, CA), Yang; Zheng-Yu (Palo Alto, CA), Zipfel; Sheila (San Mateo, CA)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:13/679,874
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,940,718

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir TABLET;ORAL 208341-001 Jun 28, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Try a Free Trial
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR ➤ Try a Free Trial
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,940,718

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,156,823 Antiviral compounds ➤ Try a Free Trial
9,809,600 Antiviral compounds ➤ Try a Free Trial
9,868,745 Antiviral compounds ➤ Try a Free Trial
8,575,135 Antiviral compounds ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,940,718

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 083711 ➤ Try a Free Trial
Australia 2011328980 ➤ Try a Free Trial
Australia 2012318253 ➤ Try a Free Trial
Australia 2015243078 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
QuintilesIMS
Cantor Fitzgerald
Cipla
Julphar
US Department of Justice
Daiichi Sankyo
UBS
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.